A Single-centre, Single-dose, Random, Open, Two-period, Cross-over Relative Bioavailability Study of Different Processes of SHR2554 Tablets in Healthy Adult Subjects
Latest Information Update: 06 Dec 2023
At a glance
- Drugs SHR-2554 (Primary)
- Indications Lymphoma
- Focus Pharmacokinetics
- Sponsors Jiangsu Hengrui Medicine Co.
Most Recent Events
- 31 Dec 2021 Planned End Date changed from 9 Oct 2021 to 29 Apr 2022.
- 31 Dec 2021 Planned primary completion date changed from 3 Oct 2021 to 6 Jan 2022.
- 31 Dec 2021 Status changed from not yet recruiting to active, no longer recruiting.